Metropolitan Life Insurance Company (MetLife)’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-7,330
| Closed | -$4.4K | – | 2386 |
|
|
2023
Q3 | $4.4K | Hold |
7,330
| – | – | ﹤0.01% | 2393 |
|
|
2023
Q2 | $9.53K | Hold |
7,330
| – | – | ﹤0.01% | 2321 |
|
|
2023
Q1 | $12.9K | Sell |
7,330
-685
| -9% | -$1.96K | ﹤0.01% | 2073 |
|
|
2022
Q4 | $25.2K | Buy |
8,015
+1,928
| +32% | +$7.48K | ﹤0.01% | 1880 |
|
|
2022
Q3 | $29.8K | Sell |
6,087
-1,982
| -25% | -$10.2K | ﹤0.01% | 1802 |
|
|
2022
Q2 | $33.4K | Hold |
8,069
| – | – | ﹤0.01% | 1745 |
|
|
2022
Q1 | $46.9K | Sell |
8,069
-22,111
| -73% | -$131K | ﹤0.01% | 1638 |
|
|
2021
Q4 | $226K | Sell |
30,180
-5,668
| -16% | -$49.2K | ﹤0.01% | 1941 |
|
|
2021
Q3 | $323K | Hold |
35,848
| – | – | ﹤0.01% | 1719 |
|
|
2021
Q2 | $429K | Buy |
35,848
+3,019
| +9% | +$34.2K | 0.01% | 1614 |
|
|
2021
Q1 | $411K | Sell |
32,829
-2,182
| -6% | -$29.4K | 0.01% | 1532 |
|
|
2020
Q4 | $546K | Hold |
35,011
| – | – | 0.01% | 1297 |
|
|
2020
Q3 | $331K | Sell |
35,011
-510
| -1% | -$5.52K | 0.01% | 1482 |
|
|
2020
Q2 | $318K | Buy |
35,521
+3,388
| +11% | +$31.4K | 0.01% | 1513 |
|
|
2020
Q1 | $205K | Sell |
32,133
-4,507
| -12% | -$33.4K | ﹤0.01% | 1575 |
|
|
2019
Q4 | $307K | Sell |
36,640
-1,652
| -4% | -$15.2K | ﹤0.01% | 1627 |
|
|
2019
Q3 | $347K | Buy |
38,292
+3,932
| +11% | +$44.1K | 0.01% | 1521 |
|
|
2019
Q2 | $370K | Buy |
34,360
+2,625
| +8% | +$27.9K | 0.01% | 1493 |
|
|
2019
Q1 | $303K | Sell |
31,735
-1,567
| -5% | -$16K | 0.01% | 1630 |
|
|
2018
Q4 | $382K | Hold |
33,302
| – | – | 0.01% | 1380 |
|
|
2018
Q3 | $564K | Hold |
33,302
| – | – | 0.01% | 1275 |
|
|
2018
Q2 | $473K | Buy |
33,302
+6,060
| +22% | +$101K | 0.01% | 1351 |
|
|
2018
Q1 | $518K | Buy |
27,242
+1,039
| +4% | +$22.2K | 0.01% | 1253 |
|
|
2017
Q4 | $430K | Sell |
26,203
-29,888
| -53% | -$445K | 0.01% | 1393 |
|
|
2017
Q3 | $841K | Buy |
56,091
+7,759
| +16% | +$85.8K | 0.01% | 1356 |
|
|
2017
Q2 | $425K | Hold |
48,332
| – | – | ﹤0.01% | 1821 |
|
|
2017
Q1 | $251K | Sell |
48,332
-1,381
| -3% | -$5.54K | ﹤0.01% | 2121 |
|
|
2016
Q4 | $152K | Buy |
49,713
+780
| +2% | +$2.84K | ﹤0.01% | 2491 |
|
|
2016
Q3 | $227K | Buy |
48,933
+1,068
| +2% | +$5.43K | ﹤0.01% | 2257 |
|
|
2016
Q2 | $277K | Hold |
47,865
| – | – | ﹤0.01% | 2107 |
|
|
2016
Q1 | $290K | Hold |
47,865
| – | – | ﹤0.01% | 1922 |
|
|
2015
Q4 | $437K | Hold |
47,865
| – | – | ﹤0.01% | 1705 |
|
|
2015
Q3 | $270K | Sell |
47,865
-574
| -1% | -$4.73K | ﹤0.01% | 2060 |
|
|
2015
Q2 | $537K | Sell |
48,439
-1,725
| -3% | -$22.2K | ﹤0.01% | 1692 |
|
|
2015
Q1 | $787K | Hold |
50,164
| – | – | 0.01% | 1341 |
|
|
2014
Q4 | $763K | Hold |
50,164
| – | – | 0.01% | 1498 |
|
|
2014
Q3 | $541K | Sell |
50,164
-6,485
| -11% | -$84.7K | ﹤0.01% | 1670 |
|
|
2014
Q2 | $865K | Buy |
56,649
+6,684
| +13% | +$96.2K | 0.01% | 1452 |
|
|
2014
Q1 | $903K | Sell |
49,965
-5,937
| -11% | -$114K | 0.01% | 1419 |
|
|
2013
Q4 | $776K | Buy |
55,902
+9,260
| +20% | +$107K | 0.01% | 1511 |
|
|
2013
Q3 | $489K | Buy |
46,642
+3,105
| +7% | +$30.8K | ﹤0.01% | 1768 |
|
|
2013
Q2 | $340K | Buy |
+43,537
| New | +$380K | ﹤0.01% | 1955 |
|
Other funds holding SGMO
WA
Metropolitan Life Insurance Company (MetLife)'s SGMO Position: Q4 2023 in Review
Metropolitan Life Insurance Company (MetLife) sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2023, closing a stake of 7,330 shares — an estimated $4.4K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in SGMO in Q2 2013 and held it in 42 quarters. The position peaked at $903K in Q1 2014. 130 funds tracked by Wall St. Rank hold SGMO as of Q4 2023.
- Metropolitan Life Insurance Company (MetLife) reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 7,330 SANGAMO THERAPEUTICS INC shares in Q4 2023, an estimated $4.4K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 42 quarters.
- Metropolitan Life Insurance Company (MetLife)'s SANGAMO THERAPEUTICS INC position peaked at $903K in Q1 2014.
- 130 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2023.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.